These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16213624)

  • 21. Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.
    Chalkidou K
    Issue Brief (Commonw Fund); 2009 Jul; 59():1-12. PubMed ID: 19639713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions.
    Dakin H; Gray A
    Med Decis Making; 2018 May; 38(4):476-486. PubMed ID: 29683792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health technology assessment in the United Kingdom.
    Drummond M; Banta D
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():178-81. PubMed ID: 19527538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-informed evidence-making.
    Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
    J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence informed decision making: the use of "colloquial evidence" at nice.
    Sharma T; Choudhury M; Kaur B; Naidoo B; Garner S; Littlejohns P; Staniszewska S
    Int J Technol Assess Health Care; 2015 Jan; 31(3):138-46. PubMed ID: 25991028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
    Littlejohns P; Barnett D; Longson C;
    Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
    Kaltenthaler E; Papaioannou D; Boland A; Dickson R
    Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).
    Buxton M
    Value Health; 2001; 4(3):212-6. PubMed ID: 11705183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
    Griffin SC; Weatherly HL; Richardson GA; Drummond MF
    Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness.
    Anderson M; Naci H; Morrison D; Osipenko L; Mossialos E
    J Clin Epidemiol; 2019 Jan; 105():50-59. PubMed ID: 30236484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments.
    Johnson FR; Backhouse M
    Value Health; 2006; 9(5):303-11. PubMed ID: 16961548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
    Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Searching for cost effectiveness thresholds in the NHS.
    Appleby J; Devlin N; Parkin D; Buxton M; Chalkidou K
    Health Policy; 2009 Aug; 91(3):239-45. PubMed ID: 19168255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.
    Carroll C; Kaltenthaler E; FitzGerald P; Boland A; Dickson R
    Health Policy; 2011 Oct; 102(2-3):136-44. PubMed ID: 21763025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.